High clinical and morphologic response using Y-90-DOTA-octreotate sequenced with Lu-177-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours
Grace Kong, Jason Callahan, Michael S Hofman, David A Pattison, Tim Akhurst, Michael Michael, Peter Eu, Rodney J Hicks
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | SPRINGER | Published : 2017
Professor Hicks is supported by a National Health and Medical Research Council of Australia practitioner fellowship and program grant. The authors would like to thank our excellent team of nuclear medicine technologists and radionuclide therapy nurses for their care of our patients.